Lab
Lab Quest
Lab Quest was paid $2.15M by Medicaid between Feb 2022 and Oct 2024, across 12 billing codes. Its largest line is 87637, Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV — 43% of everything it billed.
33Billing provider infoLAB QUEST
COSTA MESA, CA 92627
COSTA MESA, CA 92627
33aNPI1346995859assigned 02/14/2022
33bProvider typeClinical Medical Laboratory
28Total paid$2.15M
24GClaims37,447
24DCodes billed12
24AFirst – last monthFeb 2022 – Oct 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#145 of 561
Median peer was paid$222K
This provider vs. median9.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 10,338 | $380K | |
| 2023 | 1,767 | $83K | |
| 2024incomplete | 25,342 | $1.69M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 43% | 7,379 | 3,643 | $915K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 37% | 18,495 | 10,033 | $803K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 9.8% | 3,062 | 1,711 | $211K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 3.5% | 3,272 | 1,667 | $75K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 3.0% | 859 | 371 | $64K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.2% | 2,005 | 1,009 | $25K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 881 | 686 | $21K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,187 | 747 | $18K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 89 | 46 | $9K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 144 | 60 | $5K |
| 87631 | <1% | 46 | 42 | $2K | |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | <1% | 28 | 28 | $168.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNARKAR, SANJANA (PRESIDENT)